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t i a l epilepsy serum 14 (pg/dl), FT4 (pglml) and rT3 ( n g l d l ) s i g n i f i c a n t l y decreased ( t a b l e ) a f t e r ( 6 ) 2-mth CBZ therapy (20 mg/kg), uhereas an evident diminution of c i r c u l a t i n g T3 ( n g l d l ) and FT3 (pgl.1) uas found only i n the p a t i e n t n.5.
Three subjects had post-treatment serum TSH (pulml) wich rose t o hypothyroid l ev e l s p a r a l l e l y t o the 74 decrease. Serum TBG and T3 U values were n o t # i n i n a l l y modified by therapy. Since i n these cases d i r e c t e f f e c t s o f CBZ on t h y r o i d can be excluded and on c a r r i e r serum p r o t e i n s as u e l l t h e observed changes i n t h y r o i d ho! none p a t t e r n may be due t o accelerated T4 clearance, v i a s t i m u l a t i o n of t h e l i v e r microsoma1 system.Similar effects are a t t r i b u t e Twentyfour patients with GD, aged 4 to 18 years, were studied before, during and after antithyroid treatment. FT4-level was determined by Amersham RIA-kit (110 samples), TRH-test was carried out with RELEFACT (Hoechst) using Byk Mallinckrodt TSH RIA kit (56) and TSH receptor binding was detected by the assay of Shewring and Rees Smith (53). The diagnostic values of FT4-RIA and TRH-test were excellent in this material. The TSH receptor antibody results were positive (greater than 15%) in one or more samples of 15 patients out of 24, showing the nature of the disease. The prognostic value of the FT4-RIA is valuable only in short time prognosis: sometimes the relapse was indicated first by increase of the FT4-level. The bad prognosis of GD was predicted better by the TRH-test but good prognosis by the TSH receptor binding assay. The value of TRH-test and TSH receptor binding assay has been poor for choosing the adequate stopping time of antithyroid treatment in 50 % of cases.
G.F.RONDANIN1, A.BOLLATI*, G.DE PANIZZA*.Dep.of Pediatrics,Endocr.U.Univ.Milan, L.SACCO Hosp. Italy 104 Free T3 levels to monitor 1T4 therapy in congenital hypothyroid (CH) children during the first two years of life. An elevated threshold for TSH suppression has been previously described in children during the firstmonths of replacement therapy. We studied 15 children, diagnosed by neonatal CH screening during the first two years of life. All of them were clinically euthyroid in our multidisciplinary follow-up program(norma1growth rate, absence of hypo/hyperthyroidism symptoms, normal neuropsychological development). Clinical evaluation and hormonal profiles (fT3,fT4,T3,T4,TSH) were assessed every three months. We found a significant correlation between total hormones, fT4,1T4 dosage and TSH levels. TSH levels were well above the normalrange during the first year of life,varying widely between and within patientsjfT3 concentrations were not correlated with TSH levels and were well in the normal range during the study. The correlation between 1T4-TSH, fT4-TSH and lT4-fT4 shows that increasing the dose of 1T4 decreases TSH levels according to an elevated threshold for TSH inhibition by an increase in fT4 levels but TSH does not fall in the normal range at the recommended therapeutic dose. This increase in fT4 and decrease in TSH does not seem to affect the thyroid status, since fT3 does not change for individual compensatory mechanism in fT4/fT3 conversion in the usual therapeutic range; increase of 1T4 to completely inhibit TSH probably renders patients hyperthyroid.FT3 seems to be the best index for therapy.
A.TENOREX, P.LUBRANOX, MC.SALERNOX, T.QUATTRINX, C.MUSSARI* (Intr. by C.Rondanini). Dept. Pediatrics, 105 11 Faculty of Madicine, University of Naples, Italy.
Growth and maturational responses to thyroid hormones. Although congenital hypothyroidism(CH) affects linear-growth (LG), bone-maturation(BM and brain development little data exists concerning the time needed to reverse these parameters. This study investigates LC, BM and head circumference(HC)growth (indirect index of brain growth) in infants with CH at time of diagnosis and after replacement therapy.47 infants were studied (31-ectopia;8-agenesis;8-goiter). Follow-up was only in patients growing along a costant growth channel at least 9 months(n-21).
Results: a) Delay in BM at diagnosis depends on serum levels of T4(r=+.84)and age at diagnosis(r=-.83). b) 12t2mos after therapy BM shows normal progression with respect to elapsed time with no evidence of "catch-up". c) LG is markedly impaired by the time of diagnosis(27tlOdays) but shows immediate "catch-up" converting into a normal velocity after 106 Free T4 in plasma. Usefulness for monitoring thyroid replacement therapy.
The one-step RIA of free thyroxine (FT4) using a gamma-coated kit (Travenol) was used in this study. In 341 normal controls age 1 day to 18 years, it showed a transient rise at 2-3 days, then a slow decrease until age 4 years (p<.001) and a slight increase at 4-10 years, with a mean level of 18.0+3.5U. Among 21 untreated hypothyroid infants age 15-22 days, FT4 was undetectable in those with athyreosis, while in cases with dysgenetic thyroid it was variable, correlated to the w~dth of the gland (r=.77, p<.01). In 44 hypothyroid patients treated with 1-T4, a highly significant positive correlation was found after the 1st month of treatment between plasma FT4 and the daily 1-T4 dose (r= .46,p(.01), and a negative one between FT4 and plasma TSH (r= -.59, pc.001). It is concluded that measurement of FT4 offers a valuable means for control of diagnosis and treatment in congenital hypothyroidism, especially useful for avoiding both under-and overtreatment. Its correlations suggest that it is the most reliable of hormonal measurements in the follow -up of hypothyroid children.
